Results 41 to 50 of about 2,265 (188)
Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-xL [PDF]
, 2019 Mast cells (MCs) play critical roles in allergic and inflammatory reactions and contribute to multiple pathologies in the skin, in which they show increased numbers, which frequently correlates with severity. It remains ill-defined how MC accumulation is
Babina, Magda +3 more
core +1 more source
Biologic Therapies for Severe Asthma [PDF]
, 2022 Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden.
Brusselle, Guy G, Koppelman, Gerard H
core +2 more sources
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma [PDF]
International Journal of Molecular Sciences, 2021 Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation.
Corrado Pelaia +6 more
openaire +4 more sources
Az atópiás dermatitis patomechanizmusa [PDF]
, 2018 L
Steuer-Hajdu, Krisztina, Szegedi, Andrea
core +1 more source
Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
Frontiers in Immunology, 2022 Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis.
Grzegorz Kardas +4 more
doaj +1 more source
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
New England Journal of Medicine, 2021 Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment.We conducted a phase 3, multicenter, randomized, double-blind, placebo ...
Andrew, Menzies-Gow +13 more
openaire +3 more sources
Role of thymic stromal lymphopoietin (TSLP) in asthma [PDF]
, 2021 Thymic Stromal Lymphopoietin (TSLP) is a pleiotropic cytokine originally isolated from a murine thymic stromal cell line and characterized as a lymphocyte growth factor. TSLP is predominantly expressed by lung and gut epithelial cells, keratinocytes, and
Criscuolo, Gjada
core
Impact of Biologic Therapy on the Small Airways Asthma Phenotype [PDF]
, 2022 The small airways dysfunction (SAD) asthma phenotype is characterised by narrowing of airways
Chan, Rory, Lipworth, Brian J.
core +2 more sources
Dupilumab and tezepelumab in severe refractory asthma: new opportunities
Therapeutic Advances in Chronic Disease, 2022 Bronchial asthma is a chronic inflammatory condition with increasing prevalence worldwide that may present as heterogeneous phenotypes defined by the T2-mediated pattern of airway inflammation T2-high and T2-low asthma. Severe refractory asthma includes a subset of asthmatic patients who fail to control their disease despite maximal therapy and ...
Beatrice Ragnoli +8 more
openaire +4 more sources
Respiratory Research, 2020 Despite treatment with standard-of-care medications, including currently available biologic therapies, many patients with severe asthma have uncontrolled disease, which is associated with a high risk of hospitalization and high healthcare costs. Biologic
Andrew Menzies-Gow +2 more
doaj +1 more source